# Deep Genomics

> Deep Genomics is a Toronto-based biotechnology company combining RNA biology, machine learning and experimental laboratories to discover targets and design genetic medicines. Its BioFM Platform includes BigRNA, REPRESS and DeepADAR; its newly announced DeepRNAi model predicts intended and unintended gene silencing. Pharmaceutical collaborations, including a disclosed BioMarin agreement, connect its discovery work to drug development.

- **Founded:** 2015
- **Headquarters:** Toronto, Canada
- **Founders:** Brendan Frey (Co-founder; Chief Innovation Officer; founding CEO), Andrew Delong (Co-founder), Hannes Bretschneider (Co-founder), Hui Yuan Xiong (Co-founder)
- **Products:** BioFM Platform, BigRNA, REPRESS, DeepADAR, DeepRNAi
- **Notable:** Raised a US$180 million Series C in July 2021., Announced a four-indication BioMarin discovery collaboration in November 2020., Publicly introduced BigRNA in September 2023.

## Products & services

- **BioFM Platform** — Integrated biological foundation models, genomic software and lab-in-the-loop discovery workflows for target biology and molecular design. Current platform name; first naming date not established.
- **BigRNA** — Proprietary RNA foundation model trained on over a trillion genomic signals; predicts expression and regulatory effects and supports downstream therapeutic-design tasks. Publicly introduced in September 2023.
- **REPRESS** — Sequence-based model of cell-type-specific microRNA binding and mRNA degradation. Code and model access are available for non-commercial use.
- **DeepADAR** — Model of ADAR-mediated RNA editing fine-tuned with synthetic guide RNA screening data to support guide design. Publicly described by 2025.
- **DeepRNAi** — Announced October 6, 2026; predicts RISC-mediated on-target and off-target knockdown for siRNA-transcript pairs. Published company results include cell-line and rat studies and retrospective inclisiran ranking.
- **AI-enabled therapeutic discovery collaborations** — Partner programs to identify and validate disease mechanisms and oligonucleotide lead candidates. BioMarin collaboration announced in 2020.

## Achievements

- Raised a US$180 million Series C in July 2021.
- Announced a four-indication BioMarin discovery collaboration in November 2020.
- Publicly introduced BigRNA in September 2023.
- Released REPRESS for non-commercial use in 2025.
- Operates experimental facilities totaling over 10,000 square feet in Toronto and Cambridge, according to its platform page.
- DeepRNAi retrospective tests ranked the approved drug inclisiran favorably among 3,599 PCSK9-complementary sequences; this is a company-reported research result, not evidence of a newly approved Deep Genomics drug.

## Latest updates

- **2026-10** — October 6: Albi Celaj introduced DeepRNAi and reported transcriptome-wide knockdown prediction results.
- **2026-09** — September 18: CSO Greg Hoffman published an essay on AI-driven molecule design and learning from experimental screens.
- **2026-07** — July 23: Thong Q. Le appointed chair of the board.
- **2025-10** — Albi Celaj published his account of the shift from specialist models toward BigRNA.
- **2025-05** — REPRESS announced and made available for non-commercial use.

## Links

- Website: https://www.deepgenomics.com
- LinkedIn: https://www.linkedin.com/company/deep-genomics
- Twitter/X: https://twitter.com/deepgenomics
- GitHub: https://github.com/deepgenomics
- Facebook: https://facebook.com/deepgenomics

---

Profile page: https://yespress.io/deep-genomics
Published by YesPress — https://yespress.io
Last updated: 2026-10-07